This content is password protected. To view it please enter your password below:

Password:

Are you ready for the upcoming release of ICH E6 (R3) that’s expected by the end of 2024?

Join us as we examine the latest findings from the 2024 Avoca Industry Report, which gathered perspectives from sponsors, CROs, and sites on awareness, anticipated impact, and preparedness for impending ICH E6 (R3) regulatory guidance updates.

This webinar will offer valuable insights into which stakeholders might encounter the most significant challenges, the potential effects on clinical trial conduct, and the measures organizations are implementing to prepare. We’ll also explore industry perceptions on key areas of the guidance, including the importance of risk-proportionate approaches, the potential for increased site burden, and ways sponsors can mitigate these concerns.

Gain a better understanding of the industry’s current state of readiness and the critical factors to consider when implementing ICH E6 (R3). Explore opportunities for collaboration across stakeholders in the clinical trial ecosystem and how early engagement can facilitate successful implementation.

During this session, WCG experts will discuss:

• Insights into the industry’s awareness and preparedness for ICH E6 (R3).
• Identification of the potential impact on trial conduct and site burden.
• Strategies for implementing risk-proportionate approaches and mitigating site burden concerns.
• The importance of collaboration and early engagement in successful ICH E6 (R3) implementation.

Don’t miss this opportunity to engage and gain valuable insights on this important topic before new requirements are mandatory.